The Trump administration launched TrumpRx.gov on Thursday (February 5, 2026), a website designed to help Americans purchase prescription dr...

Novo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...

Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The c...

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

President Trump announced a deal with Eli Lilly and Novo Nordisk to significantly lower the cost of weight loss drugs like Wegovy and Zepbo...

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines...

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...

Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sa...

Novo Nordisk launches Wegovy, a weekly weight-loss injectable, in India. The drug is available in five dosages, costing between Rs 17,345 a...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gain...

Novo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market. The company aims...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participant...

A new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating habits. The stud...

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical cost...

In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...